Literature DB >> 856019

Comparative susceptibility of anaerobic bacteria to ticarcillin, cefoxitin, metronidazole, and related antimicrobial agents.

D K Henderson, A W Chow, L B Guze.   

Abstract

The in vitro antimicrobial activity of two newer agents, ticarcillin and cefoxitin, against 204 recent clinical isolates of anaerobic bacteria was determined by an agar dilution technique, and compared to their related compounds carbenicillin, cephalothin, and penicillin, as well as metronidazole, clindamycin, and chloramphenicol. Ticarcillin was similar to carbenicillin, and cefoxitin was more active than cephalothin. At readily achievable blood concentrations of each antimicrobial agent, ticarcillin was slightly less active than clindamycin against Bacteroides fragilis. Cefoxitin was superior to cephalothin and penicillin against B. fragilis. Penicillin remained highly active against all obligate anaerobes other than B. fragilis. Metronidazole, while highly effective against B. fragilis and Clostridium perfringens, was only intermediately effective against anaerobic gram-positive cocci and relatively inactive against nonsporulating anaerobic gram-positive bacilli. Further evaluation of the clinical efficacy of ticarcillin, carbenicillin, and cefoxitin against anaerobic infections is indicated.

Entities:  

Mesh:

Substances:

Year:  1977        PMID: 856019      PMCID: PMC352049          DOI: 10.1128/AAC.11.4.679

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  12 in total

1.  Summary of a workshop on clindamycin colitis.

Authors:  G T Keusch; D H Present
Journal:  J Infect Dis       Date:  1976-05       Impact factor: 5.226

2.  Susceptibility of anaerobes to cefoxitin and other cephalosporins.

Authors:  F P Tally; N V Jacobus; J G Bartlett; S L Gorbach
Journal:  Antimicrob Agents Chemother       Date:  1975-02       Impact factor: 5.191

3.  Clindamycin-associated colitis. A prospective study.

Authors:  F J Tedesco; R W Barton; D H Alpers
Journal:  Ann Intern Med       Date:  1974-10       Impact factor: 25.391

4.  Clindamycin-associated colitis.

Authors:  L E Cohen; C J McNeill; R F Wells
Journal:  JAMA       Date:  1973-03-19       Impact factor: 56.272

5.  Clinical evaluation of carbenicillin in the treatment of infection due to anaerobic bacteria.

Authors:  W Fiedelman; C D Webb
Journal:  Curr Ther Res Clin Exp       Date:  1975-09

6.  Comparative study of the in vitro antibacterial activity of cefoxitin, cefuroxine, and cephaloridine.

Authors:  R Norrby; J E Brorsson; S Seeberg
Journal:  Antimicrob Agents Chemother       Date:  1976-03       Impact factor: 5.191

7.  Bacteroides fragilis resistant to the administration of clindamycin.

Authors:  J S Salaki; R Black; F P Tally; J W Kislak
Journal:  Am J Med       Date:  1976-03       Impact factor: 4.965

8.  Management of anaerobic infections.

Authors:  S M Finegold; J G Bartlett; A W Chow; D J Flora; S L Gorbach; E J Harder; F P Tally
Journal:  Ann Intern Med       Date:  1975-09       Impact factor: 25.391

9.  Cefoxitin, a semisynthetic cephamycin antibiotic: resistance to beta-lactamase inactivation.

Authors:  H R Onishi; D R Daoust; S B Zimmerman; D Hendlin; E O Stapley
Journal:  Antimicrob Agents Chemother       Date:  1974-01       Impact factor: 5.191

10.  In vitro studies of alpha-carboxyl-3-thienylmethyl penicillin, a new semisynthetic penicillin.

Authors:  G P Bodey; B Deerhake
Journal:  Appl Microbiol       Date:  1971-01
View more
  10 in total

1.  Identification and susceptibility patterns of anaerobic bacteria isolated from clinical specimens during a one-year period.

Authors:  A C Rodloff; G Görtz; H Ponnath; H Hahn
Journal:  Infection       Date:  1984 Nov-Dec       Impact factor: 3.553

2.  Susceptibility of 40 lactobacilli to six antimicrobial agents with broad gram-positive anaerobic spectra.

Authors:  A S Bayer; A W Chow; N Concepcion; L B Guze
Journal:  Antimicrob Agents Chemother       Date:  1978-11       Impact factor: 5.191

3.  Comparison of the activity of ionophores with other antibacterial agents against anaerobes.

Authors:  K Watanabe; J Watanabe; S Kuramitsu; H B Maruyama
Journal:  Antimicrob Agents Chemother       Date:  1981-04       Impact factor: 5.191

4.  Susceptibility of the Bacteroides fragilis group in the United States in 1981.

Authors:  F P Tally; G J Cuchural; N V Jacobus; S L Gorbach; K E Aldridge; T J Cleary; S M Finegold; G B Hill; P B Iannini; R V McCloskey; J P O'Keefe; C L Pierson
Journal:  Antimicrob Agents Chemother       Date:  1983-04       Impact factor: 5.191

5.  Propionibacteria as a cause of shunt and postneurosurgical infections.

Authors:  P R Skinner; A J Taylor; H Coakham
Journal:  J Clin Pathol       Date:  1978-11       Impact factor: 3.411

6.  [Antibiotic resistance of anaerobic bacteria (author's transl)].

Authors:  W Niederau; U Höffler; G Pulverer
Journal:  Infection       Date:  1982       Impact factor: 3.553

7.  Antimicrobial susceptibilities of 1,292 isolates of the Bacteroides fragilis group in the United States: comparison of 1981 with 1982.

Authors:  G J Cuchural; F P Tally; N V Jacobus; S L Gorbach; K Aldridge; T Cleary; S M Finegold; G Hill; P Iannini; J P O'Keefe
Journal:  Antimicrob Agents Chemother       Date:  1984-08       Impact factor: 5.191

Review 8.  Cefoxitin: a review of its antibacterial activity, pharmacological properties and therapeutic use.

Authors:  R N Brogden; R C Heel; T M Speight; G S Avery
Journal:  Drugs       Date:  1979-01       Impact factor: 9.546

9.  Anaerobic infection in cancer patients: comparative evaluation of clindamycin and cefoxitin.

Authors:  J Klastersky; L Coppens; G Mombelli
Journal:  Antimicrob Agents Chemother       Date:  1979-09       Impact factor: 5.191

10.  In vitro activity of N-formimidoyl thienamycin, moxalactam, and other new beta-lactam agents against Bacteroides fragilis: contribution of beta-lactamase to resistance.

Authors:  J E Brown; V E Del Bene; C D Collins
Journal:  Antimicrob Agents Chemother       Date:  1981-02       Impact factor: 5.191

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.